Nplate Related Clinical Trials
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin [Completed]
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma [Completed]
Open Label Extension Study of AMG 531 in Japanese Subjects With ITP [Completed]
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) [Completed]
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy [Suspended]
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) [Completed]
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) [Completed]
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) [Completed]
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia [Suspended]
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim [Completed]
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP [Completed]
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura [Completed]
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy [Completed]
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy [Completed]
Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia [Recruiting]
Interventional Study in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim [Completed]
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid [Completed]
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents [Completed]
Safety Study of AMG 531 in Japanese Subjects With ITP [Completed]
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training [Recruiting]
Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP. [Recruiting]
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia [Recruiting]
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects [Completed]
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura [Recruiting]
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura [Completed]
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects [Completed]
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) [Completed]
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia [Recruiting]
Prevention of Thrombocytopenia in Glioblastoma Patients [Recruiting]
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma [Completed]
NplateŽ Pregnancy Exposure Registry [Terminated]
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Terminated]
Indirect Comparison Between Eltrombopag & Romiplostim [Completed]
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) [Completed]
Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety. [Completed]
Evaluating the Safety and Efficacy of AMG531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura(ITP) [Completed]
Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults [Completed]
Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell [Recruiting]
Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology [Completed]
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) [Recruiting]
TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients. [Recruiting]
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP [Recruiting]
Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia [Recruiting]
|
